SI1940465T1 - Nova uporaba protiteles proti IL-1 beta - Google Patents

Nova uporaba protiteles proti IL-1 beta

Info

Publication number
SI1940465T1
SI1940465T1 SI200631412T SI200631412T SI1940465T1 SI 1940465 T1 SI1940465 T1 SI 1940465T1 SI 200631412 T SI200631412 T SI 200631412T SI 200631412 T SI200631412 T SI 200631412T SI 1940465 T1 SI1940465 T1 SI 1940465T1
Authority
SI
Slovenia
Prior art keywords
novel use
1beta antibodies
1beta
antibodies
novel
Prior art date
Application number
SI200631412T
Other languages
English (en)
Inventor
Phil Lowe
Hermann Gram
Thomas Jung
Timothy Wright
Trevor Mundel
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37806690&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1940465(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of SI1940465T1 publication Critical patent/SI1940465T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/245—IL-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/246—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SI200631412T 2005-10-26 2006-10-24 Nova uporaba protiteles proti IL-1 beta SI1940465T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US73043505P 2005-10-26 2005-10-26
US74212505P 2005-12-02 2005-12-02
EP06826560A EP1940465B1 (en) 2005-10-26 2006-10-24 Novel use of anti il-1beta antibodies
PCT/US2006/041479 WO2007050607A2 (en) 2005-10-26 2006-10-24 Novel use of il-1beta compounds

Publications (1)

Publication Number Publication Date
SI1940465T1 true SI1940465T1 (sl) 2012-10-30

Family

ID=37806690

Family Applications (2)

Application Number Title Priority Date Filing Date
SI200631412T SI1940465T1 (sl) 2005-10-26 2006-10-24 Nova uporaba protiteles proti IL-1 beta
SI200632245T SI2848258T1 (sl) 2005-10-26 2006-10-24 Zdravljenje familiarne mediteranske vročice z anti IL-1beta protitelesi

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI200632245T SI2848258T1 (sl) 2005-10-26 2006-10-24 Zdravljenje familiarne mediteranske vročice z anti IL-1beta protitelesi

Country Status (29)

Country Link
US (8) US8105587B2 (sl)
EP (5) EP2332577A1 (sl)
JP (4) JP2009513645A (sl)
KR (3) KR20170038131A (sl)
CN (2) CN102861332A (sl)
AU (1) AU2006306280B2 (sl)
BR (1) BRPI0617830B8 (sl)
CA (3) CA2898369C (sl)
CY (4) CY1113378T1 (sl)
DK (2) DK1940465T3 (sl)
ES (3) ES2389110T3 (sl)
HK (3) HK1121041A1 (sl)
HU (2) HUE036973T2 (sl)
IL (4) IL190545A (sl)
JO (2) JO2826B1 (sl)
LT (3) LT2848258T (sl)
LU (2) LU92326I2 (sl)
MA (1) MA29919B1 (sl)
NO (2) NO345888B1 (sl)
NZ (1) NZ567222A (sl)
PH (2) PH12013501287A1 (sl)
PL (2) PL2848258T3 (sl)
PT (2) PT2848258T (sl)
RU (2) RU2468817C2 (sl)
SI (2) SI1940465T1 (sl)
TN (1) TNSN08189A1 (sl)
TR (1) TR201802449T4 (sl)
TW (3) TWI388335B (sl)
WO (1) WO2007050607A2 (sl)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102861332A (zh) * 2005-10-26 2013-01-09 诺瓦提斯公司 IL-1β化合物的新用途
EP2468302A1 (en) * 2007-05-29 2012-06-27 Novartis AG New indications for anti-IL-1beta therapy
AU2012203932B2 (en) * 2007-05-29 2014-04-24 Novartis Ag New indications for anti-IL-I-beta therapy
JP5607613B2 (ja) * 2008-06-06 2014-10-15 ゾーマ （ユーエス） リミテッド ライアビリティ カンパニー 関節リウマチの治療のための方法
EP2196476A1 (en) 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CA2774326C (en) 2009-09-14 2023-11-07 Donald Bellgrau Modulation of yeast-based immunotherapy products and responses
CN102655880A (zh) * 2009-10-15 2012-09-05 雅培制药有限公司 Il-1结合蛋白
UY33386A (es) * 2010-05-14 2011-12-30 Abbott Laboratoires Proteínas de unión a il-1
WO2012121775A2 (en) * 2010-12-21 2012-09-13 Abbott Laboratories Dual variable domain immunoglobulins and uses thereof
WO2012154987A1 (en) 2011-05-10 2012-11-15 Nestec Sa Methods of disease activity profiling for personalized therapy management
WO2017153936A1 (en) 2016-03-10 2017-09-14 Novartis Ag Chemically modified messenger rna's
WO2018220588A1 (en) 2017-05-31 2018-12-06 Nestec S.A. Methods for assessing mucosal healing in crohn's disease patients
WO2018235056A1 (en) 2017-06-22 2018-12-27 Novartis Ag IL-1BETA BINDING ANTIBODIES FOR USE IN THE TREATMENT OF CANCER
TW201946652A (zh) 2018-05-09 2019-12-16 瑞士商諾華公司 康納單抗(canakinumab)之用途
WO2020128637A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1 binding antibodies in the treatment of a msi-h cancer
BR112021011351A2 (pt) 2018-12-21 2021-11-16 Novartis Ag Uso de anticorpos il-1 beta no tratamento ou prevenção de síndrome mielodisplásica
WO2020128613A1 (en) 2018-12-21 2020-06-25 Novartis Ag Use of il-1beta binding antibodies
JP2022514087A (ja) 2018-12-21 2022-02-09 ノバルティス アーゲー ＩＬ－１β結合抗体の使用
TWI793503B (zh) * 2020-01-20 2023-02-21 美商美國禮來大藥廠 抗IL-1β抗體
KR20230109107A (ko) * 2022-01-10 2023-07-19 (주)지아이이노베이션 글루카곤-유사 펩타이드-1 및 인터루킨-1 수용체 길항제를 포함하는 퇴행성 뇌질환 예방 또는 치료용 약학 조성물

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5350683A (en) 1990-06-05 1994-09-27 Immunex Corporation DNA encoding type II interleukin-1 receptors
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
DK0814159T3 (da) 1990-08-29 2005-10-24 Genpharm Int Transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
WO1995001997A1 (en) * 1993-07-09 1995-01-19 Smithkline Beecham Corporation RECOMBINANT AND HUMANIZED IL-1β ANTIBODIES FOR TREATMENT OF IL-1 MEDIATED INFLAMMATORY DISORDERS IN MAN
EP0690673A4 (en) 1993-12-14 1996-05-29 Univ Pittsburgh SYSTEMIC GENETIC TREATMENT OF TISSUE DISEASES
US6258823B1 (en) 1996-07-12 2001-07-10 Ariad Pharmaceuticals, Inc. Materials and method for treating or preventing pathogenic fungal infection
US6294170B1 (en) 1997-08-08 2001-09-25 Amgen Inc. Composition and method for treating inflammatory diseases
WO2000047619A1 (en) 1999-02-10 2000-08-17 Interleukin Genetics, Inc. Therapeutics and diagnostics based on an il-1b mutation
PL352944A1 (en) * 1999-07-16 2003-09-22 Leo Pharma Aminobenzophenones as inhibitors of il-1beta and tnf-alpha
ATE264863T1 (de) 1999-08-24 2004-05-15 Ariad Gene Therapeutics Inc 28-epirapaloge
GB0001448D0 (en) * 2000-01-21 2000-03-08 Novartis Ag Organic compounds
EP1282435A2 (en) 2000-05-12 2003-02-12 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
GB0020685D0 (en) * 2000-08-22 2000-10-11 Novartis Ag Organic compounds
DE60140201D1 (en) 2000-11-07 2009-11-26 Novartis Ag Indolylmaleimidderivative als proteinkinase-c-inhibitoren
WO2003010282A2 (en) * 2001-07-26 2003-02-06 Eli Lilly And Company Interleukin-1 beta antibodies
PL374118A1 (en) 2001-08-07 2005-10-03 Immunex Corporation Interleukin-1 receptors in the treatment of diseases
WO2003049256A2 (en) 2001-12-01 2003-06-12 Iskra Wind Turbine Manufacturers Limited Ac synchronous generator incorporating a braking mechansim
KR200268109Y1 (ko) 2001-12-06 2002-03-15 김정훈 편평형 무정류자 진동모터
IL162734A0 (en) 2002-02-01 2005-11-20 Ariad Gene Therapeutics Inc Phosphorus-containing compounds & uses thereof
WO2003063799A2 (en) 2002-02-01 2003-08-07 Omeros Corporation Compositions and methods for systemic inhibition of cartilage degradation
MXPA04007694A (es) 2002-02-11 2004-11-10 Arkion Life Sciences Llc Factor inhibidor de citosina purificada.
PE20040079A1 (es) 2002-04-03 2004-04-19 Novartis Ag Derivados de indolilmaleimida
KR20050084224A (ko) 2002-12-09 2005-08-26 더 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 야누스 티로신 키나제 3을 선택적으로 저해하는 방법
CN1780855B (zh) * 2003-01-24 2011-03-30 应用分子进化公司 人IL-1β拮抗剂
GB0303337D0 (en) * 2003-02-13 2003-03-19 Celltech R&D Ltd Biological products
US20050209162A1 (en) 2003-11-10 2005-09-22 Amit Roy Methods for monitoring IL-18
WO2005066156A1 (en) 2004-01-12 2005-07-21 Cytopia Research Pty Ltd Selective kinase inhibitors
JP4989456B2 (ja) * 2004-02-26 2012-08-01 ベイラー リサーチ インスティテュート 関節炎の全身処置のための組成物および方法
CA2567080A1 (en) 2004-05-27 2005-12-15 Vertex Pharmaceuticals Incorporated Ice inhibitors for the treatment of autoinflammatory diseases
WO2005117945A1 (en) * 2004-06-04 2005-12-15 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat autoinflammatory disease
JP2009501128A (ja) 2005-01-20 2009-01-15 ユニバーシティー オブ ロチェスター 炎症疾患および炎症障害の研究および処置のための組成物および方法
AU2006227165B2 (en) 2005-03-18 2011-11-10 Microbia, Inc. Production of carotenoids in oleaginous yeast and fungi
MX2007016032A (es) 2005-06-21 2008-03-10 Xoma Technology Ltd Anticuerpos de enlace a il-1-beta y fragmentos de los mismos.
CN102861332A (zh) 2005-10-26 2013-01-09 诺瓦提斯公司 IL-1β化合物的新用途

Also Published As

Publication number Publication date
CY1113378T1 (el) 2015-11-04
IL245387A0 (en) 2016-06-30
CN101291693A (zh) 2008-10-22
JO2826B1 (en) 2014-09-15
HK1252316A1 (zh) 2019-05-24
TR201802449T4 (tr) 2018-03-21
US20130171167A1 (en) 2013-07-04
EP3332807A3 (en) 2018-06-20
CA2626214A1 (en) 2007-05-03
RU2468817C2 (ru) 2012-12-10
US8409576B2 (en) 2013-04-02
RU2012133522A (ru) 2014-02-20
US20170218063A1 (en) 2017-08-03
CY2018018I2 (el) 2018-12-12
IL245387B (en) 2019-09-26
CA2963828A1 (en) 2007-05-03
EP1940465A2 (en) 2008-07-09
NO20200810A1 (no) 2008-07-22
PT2848258T (pt) 2018-03-20
JP2009513645A (ja) 2009-04-02
LTC2848258I2 (lt) 2019-08-12
HK1121041A1 (en) 2009-04-17
EP3332807B1 (en) 2023-02-22
KR101518064B1 (ko) 2015-05-06
PH12013501287B1 (en) 2016-02-01
PL1940465T3 (pl) 2013-01-31
EP1940465B1 (en) 2012-08-01
AU2006306280A1 (en) 2007-05-03
RU2571563C2 (ru) 2015-12-20
NO345888B1 (no) 2021-09-27
NO20082344L (no) 2008-07-22
JP2016020377A (ja) 2016-02-04
KR101749388B1 (ko) 2017-06-20
CA2626214C (en) 2016-06-21
US20120039910A1 (en) 2012-02-16
EP4218815A3 (en) 2024-03-27
PT1940465E (pt) 2012-10-03
TNSN08189A1 (en) 2009-10-30
TWI537003B (zh) 2016-06-11
KR20170038131A (ko) 2017-04-05
US20240083997A1 (en) 2024-03-14
CA2898369C (en) 2017-06-20
TWI626056B (zh) 2018-06-11
TW200803898A (en) 2008-01-16
CY2013046I2 (el) 2015-11-04
LUC00078I2 (fr) 2018-08-14
NZ567222A (en) 2011-07-29
EP2848258B1 (en) 2017-12-13
LU92326I2 (fr) 2014-02-05
RU2008120625A (ru) 2010-01-20
US20210147533A1 (en) 2021-05-20
US20180201674A1 (en) 2018-07-19
BRPI0617830B8 (pt) 2021-05-25
EP2848258A1 (en) 2015-03-18
IL277406A (en) 2020-11-30
SI2848258T1 (sl) 2018-03-30
WO2007050607A3 (en) 2007-06-28
US20150322148A1 (en) 2015-11-12
EP3332807A2 (en) 2018-06-13
ES2389110T3 (es) 2012-10-23
CN101291693B (zh) 2012-10-03
PL2848258T3 (pl) 2018-06-29
PH12013501287A1 (en) 2016-02-01
JP2017206552A (ja) 2017-11-24
BRPI0617830B1 (pt) 2020-10-20
IL258983A (en) 2018-06-28
DK2848258T3 (en) 2018-03-19
DK1940465T3 (da) 2012-10-22
CN102861332A (zh) 2013-01-09
CY2013046I1 (el) 2015-11-04
TW201617097A (zh) 2016-05-16
NO345140B1 (no) 2020-10-12
US9649377B2 (en) 2017-05-16
HUS1800025I1 (hu) 2018-07-30
IL258983B (en) 2020-10-29
JOP20140120B1 (ar) 2021-08-17
PH12020500559A1 (en) 2021-06-14
TW201302220A (zh) 2013-01-16
EP4218815A2 (en) 2023-08-02
TWI388335B (zh) 2013-03-11
WO2007050607A2 (en) 2007-05-03
HK1204767A1 (en) 2015-12-04
HUE036973T2 (hu) 2018-08-28
LTC1940465I2 (lt) 2017-12-11
CY2018018I1 (el) 2018-12-12
JP2013166757A (ja) 2013-08-29
KR20150013834A (ko) 2015-02-05
MA29919B1 (fr) 2008-11-03
US20080286266A1 (en) 2008-11-20
JP6061747B2 (ja) 2017-01-18
CY1120018T1 (el) 2018-12-12
EP2332577A1 (en) 2011-06-15
LU92326I9 (sl) 2019-01-16
IL190545A0 (en) 2008-11-03
CA2898369A1 (en) 2007-05-03
LT2848258T (lt) 2018-02-26
IL190545A (en) 2016-09-29
ES2662420T3 (es) 2018-04-06
AU2006306280B2 (en) 2010-06-17
BRPI0617830A2 (pt) 2011-08-09
US8105587B2 (en) 2012-01-31
LTPA2018506I1 (lt) 2018-06-25
ES2944067T3 (es) 2023-06-19
KR20080059598A (ko) 2008-06-30
JP6286403B2 (ja) 2018-02-28

Similar Documents

Publication Publication Date Title
HK1252316A1 (zh) IL-1β抗體的用途
IL266336A (en) Fixed dose of her antibodies
HK1122579A1 (en) Uses of anti-cd40 antibodies
AP2552A (en) P-cadherin antibodies
EP1869192A4 (en) FRAME MIXTURE OF ANTIBODIES
PT2343320T (pt) Anticorpos anti-gitr e as suas utilizações
GB0517487D0 (en) Antibodies
GB0505975D0 (en) Novel use of peptide
HK1161122A1 (en) Use of 24-norudca 24-norudca
EP1931370A4 (en) USE OF DES-ASPARTATE-ANGIOTENSIN I
EP1896047A4 (en) ANTI-GFRALPHA3 ANTIBODIES
GB0505489D0 (en) Antibodies
GB0512278D0 (en) Antibodies
GB0505054D0 (en) Antibodies
ZA200802876B (en) Novel use of IL-1beta compounds
GB0506945D0 (en) Human antibodies
GB0503190D0 (en) Human antibodies
GB0502201D0 (en) Human antibodies
GB0519883D0 (en) Antibodies
TWM292440U (en) Improved structure of sander